Trial Profile
A randomized, double blind, parallel group study to examine the effect of multiple doses of CJ-040,714 on distal esophageal acid exposure an patients with erosive gastro-esophageal reflux disease (GERD).
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Aug 2019
Price :
$35
*
At a glance
- Drugs CJ 040,714 (Primary)
- Indications Gastro-oesophageal reflux
- Focus Therapeutic Use
- 05 Aug 2019 Status changed from recruiting to completed.
- 17 May 2011 New trial record